Review on the annual cancer risk of Barrett's esophagus in persons with symptoms of gastroesophageal reflux disease

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5465-5474

  Lenglinger, Johannes ^a   Riegler, Martin ^a   Cosentini, Enrico ^a   Asari, Reza ^a   Mesteri, Ildiko ^a   Wrba, Fritz ^a   Schoppmann, Sebastian F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; High grade dysplasia; Incidence; Low grade dysplasia; Prevalence; Radiofrequency ablation

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CARDIOVASCULAR DISEASE; COMORBIDITY; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HIATUS HERNIA; HUMAN; LIFE EXPECTANCY; NEOPLASM; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; RISK FACTOR; SMOKING;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84872544498     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Becher A and Dent J: Systematic review: ageing and gastrooesophageal reflux disease symptoms, esophageal function and reflux oesophagitis. Aliment Pharmacol Ther 33(4): 442-454, 2011.
2. Kamolz T and Velanovich V: The impact of disease and treatment on health-related quality of life in patients suffering from GERD. In: Gastroesophageal Reflux Disease, Principles of Disease, Diagnosis and Treatment. Granderath FA, Kamolz T, Pointner R (eds.). Springer, Vienna, pp. 287-298, 2006.
3. Malfertheiner P, Nocon M, Vieth M et al: Evolution of gastrooesophageal reflux disease over 5 years under routine medical care - the ProGERD study. Aliment Pharmacol Ther 35(1): 154-164, 2012.
4. Rieder F, Biancani P, Harnett K, Yerian L and Falk GW: Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol 298(5): G571-581, 2010.
5. Goldman A, Chen HD, Roesly HB, Hill KA, Tome ME, Dvorak B, Bernstein H and Dvorak K: Characterization of squamous esophageal cells resistant to bile acids at acidic pH: Implication for Barrett's esophagus pathogenesis. Am J Physiol 300(2): G292-G302, 2010.
6. Huo X, Juergens S, Zhang X, Rezaei D, Yu C, Strauch ED, Wang JY, Cheng E, Meyer F, Wang DH, Zhang Q, Spechler SJ and Souza RF: Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kB activation in benign Barrett's epithelial cells. Am J Physiol 301(2): G278-G286, 2011.
7. Zhang HY, Hormi Carver K, Zhang X, Spechler SJ and Souza RF: In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res 69(23): 9083-89, 2009.
8. Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, Wang DH, Spechler SJ and Souza RF: Cancer-related inflammation and Barrett's carcinogenesis: Interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol 300(3): G454-G460, 2011.
9. Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS and Orlando RC: Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol 99(1): 13-22, 2004.
10. Barlow WJ and Orlando RC: The pathogenesis of heartburn in nonerosive reflux disease: A unifying hypothesis. Gastroenterology 128(3): 771-778, 2005.
11. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM and Spechler SJ: Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 137(5): 1776-1784, 2009.
12. Sarosi G, Brown G, Jaiswal K, Feagins LA, Lee E, Crook TW, Souza RF, Zou YS, Shay JW and Spechler SJ: Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esoph 21(1): 43-50, 2008.
13. Chandrasoma PT: Columnar-lined esophagus: What it is and what it tells us. Eur Surg 38(3): 197-209, 2006.
14. Ringhofer C, Lenglinger J, Izay B, Kolarik K, Zacherl J, Eisler M, Wrba F, Chandrasoma PT, Cosentini EP, Prager G and Riegler M: Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr 120(11): 350-359, 2008.
15. Glickman JN, Spechler SJ, Souza RF, Lunsford T, Lee E and Odze RD: Multilayered epithelium in mucosal biopsy specimens from the gastroesphageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol 33(6): 818-825, 2009.
16. Öberg S, Peters JH, DeMeester TR, Chandrasoma P, Hagen JA, Ireland AP, Ritter MP, Mason RJ, Crookes P and Bremner CG: Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 226(4): 522-32, 1997.
17. Lenglinger J, Eisler M, Wrba F, Zacherl J, Prager G and Riegler FM: Update: histopathology-based definition of gastroesophageal reflux disease and Barrett's esophagus. Eur Surg 40(4): 165-175, 2008.
18. Lenglinger J, Izay B, Eisler M, Wrba F, Zacherl J, Prager G and Riegler M: Barrett's esophagus: Size of the problem and diagnostic value of a novel histopathology classification. Eur Surg 41(1): 26-39, 2009.
19. Goldblum JR: Controversies in the diagnosis of Barrett's esophagus and Barrett-related dysplasia. Arch Pathol Lab Med 134(10): 1479-1484, 2010.
20. Mueller J, Werner M and Stolte M: Barrett's esophagus: Histopathologic definitions and diagnostic criteria. World J Surg 28(2): 148-54, 2004.
21. Odze RD: What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr Opin Gastroenterol 27(4): 389-396, 2011.
22. Chandrasoma P, Wijetunge S, DeMeester S, Demeester S, Hagen J and Demeester T: Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am J Surg Pathol 36(1): 1-7, 2011.
23. Spechler SJ, Fitzgerald RC, Prasad GA and Wang KK: History, molecular mechanism, and endoscopic treatment of Barrett's esophagus. Gastroenterology 138(3): 854-69, 2010.
24. Spechler SJ: Screening and surveillance for Barrett's esophagus - an unresolved dilemma. Nat Clin Pract Gastroenterol Hepatol 4(9): 470-1, 2007.
25. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT and Murray LJ: Risk of malignant progression in Barrett's esophagus patients: results from a large populationbased study. J Natl Cancer Inst 103(13): 1049-1057, 2011.
26. Chandrasoma P, Wijetunge S, Ma Y, Demeester S, Hagen J and Demeester T: The dilated distal esophagus: A new entity that is the pathologic basis of early gastroesophageal reflux disease. Am J Surg Pathol 35(12): 1873-1881, 2011.
27. Chandrasoma P, Wijetunge S, DeMeester SR, Hagen J and Demeester TR: The histologic squamo-oxyntic gap: An accurate and reproducible diagnostic marker of gastroesophageal reflux disease. Am J Surg Pathol 34(11): 1574-1581, 2010.
28. Ronkainen J, Aro P, Storskrubb, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ and Agréus L: Prevalence of Barrett's esophagus in the general population: An endoscopy study. Gastroenterology 129 (6): 1825-1831, 2005.
29. Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS and Hur C: The prevalence of Barrett's esophagus in the US: Estimates from a simulation model confirmed by SEER data. Dis Esoph 23(6): 451-457, 2010.
30. Gerson LB, Shetler K and Triadafilopoulos G: Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123(2): 461-467, 2002.
31. Siewert JR, Stein HJ and Feith M: Adenocarcinoma of the esophago-gastric junction. Scand J Surg 95(4): 260-269, 2006.
32. Schoppmann SF, Prager G, Langer FB, Riegler FM, Kabon B, Fleischmann E and Zacherl J: Open versus minimally invasive esophagectomy: A single-center case-controlled study. Surg Endosc 24(12): 3044-3053, 2010.
33. Sharma P, Falk GW, Weston AP, Reker D, Johnston M and Sampliner RE: Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 4(5): 566-572, 2010.
34. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT and Funch-Jensen P: Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 365(15): 1375-1383, 2011.
35. De Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA and Kuipers EJ: Risk of malignant progression in patients with Barrett's oesophagus: Dutch nationwide cohort study. Gut 59(8): 1030-1036, 2010.
36. Jung KW, Talley NJ, Romero Y, Katzka DA, Schleck CD, Zinsmeister AR, Dunagan KT, Lutzke LS, Wu TT, Wang KK, Frederickson M, Geno DM, Locke GR and Prasad GA: Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 106(8): 1447-1455, 2011.
37. Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, Singh M, Singh V, Chuang KY, Boolchand V, Gavini H, Kuczynski J, Sud P, Reddymasu S, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Lieberman DA, Sampliner RE and Sharma P: Patients with nondysplastic Barrett's esophagus have a low risk for developing dysplasia or esophageal cancer. Clin Gastroenterol Hepatol 9(3): 220-227, 2011.
38. Wani S, Falk GW, Post J, Yerian L, Hall M, Wang A, Gupta N, Gaddam S, Singh M, Singh V, Chuang KY, Boolchand V, Gavini H, Kuczynski J, Sud P, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Goldblum J, Lieberman DA, Sampliner RE and Sharma P: Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 141(4): 1179-1186, 2011.
39. Thomas T, Abrams KR, De Caestecker JS and Robinson RJ: Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharm 26(11-12): 1465-1477, 2007.
40. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT and Murray L: The incidence of esophageal cancer and highgrade dysplasia in Barrett's esophagus: A systematic review and meta-analysis. Am J Epidemiol 168(3): 237-249, 2008.
41. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S and Sharma P: Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: A meta-analysis. Gastrointest Endosc 67(3): 394-398, 2008.
42. Sikkema M, De Jonge PJF, Steyerberg EW and Kuipers EJ: Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 8(3): 235-244, 2010.
43. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S and Howden CW: The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-analysis. Gut 61(7): 970-976, 2012.
44. Sikkema M, Looman CWN, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, van Vuuren AJ, Bode WA, van der Valk H, Ouwendijk RJ, Giard R, Lesterhuis W, Heinhuis R, Klinkenberg EC, Meijer GA, ter Borg F, Arends JW, Kolkman JJ, van Baarlen J, de Vries RA, Mulder AH, van Tilburg AJ, Offerhaus GJ, ten Kate FJ, Kusters JG, Kuipers EJ and Siersema PD: Predictors for neoplastic progression in patients with Barrett's esophagus: A prospective cohort study. Am J Gastroenterol 106(7): 1231-1238, 2011.
45. Lagergren J, Bergström R, Lindgren A and Nyrén O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Eng J Med 340(11): 825-831, 1999.
46. Dulai GS, Guha S, Kahn KL, Gornbein J and Weinstein WM: Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: A systematic review. Gastroenterology 122(1): 26-33, 2002.
47. Corley DA, Levin TR, Habel LA, Weiss NS and Buffler PA: Surveillance and survival in Barrett's adenocarcinomas: A population-based study. Gastroenterology 122(3): 633-640, 2002.
48. Rubenstein JH, Mattek N and Eisen G: Age- and sex-specific yield of Barrett's esophagus by endoscopy indication. Gastrointest Endosc 71(1): 21-27, 2010.
49. Kadri S, Lao-Sirieix P and Fitzgerald RC: Developing a nonendoscopic screening test for Barrett's esophagus. Biomark Med 5(3): 397-404, 2011.
50. Arora G, Basra S, Roorda AK and Triadafilopoulos G: Radiofrequency ablation for Barrett's esophagus. Eur Surg 41(1): 19-25, 2009.
51. Fleischer DE, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, Chang KJ, Muthasamy R, Lightdale CJ, Santiago N, Pleskow DK, Dean PJ and Wang KK: Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 42(10): 781-789, 2010.
52. Inadomi JM, Somsouk M, Madanick RD, Thomas JP and Shaheen NJ: A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 136(7): 2101-2114, 2009.
53. Krsihnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L and Komanduri S: Increased risk for persistent intestinal metaplasia with Barrett's esophagus and uncontrolled reflux before radiofrequency ablation. Gastroenterology 143(3): 576-581, 2012.